More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

How did pharmaceutical and biopharmaceutical companies fare in the first quarter? Now that financial results are in, an analysis of first-quarter results. The pharmaceutical and biopharmaceutical industry offered mixed revenue results for the...
DCAT Value Chain Insights

In 2013, 17 new orphan drugs were launched in the US, the highest number of orphan drugs introduced to the US market in more than a decade. As pharmaceutical companies seek ways to improve R&D productivity and reach commercialization, they are...
DCAT Value Chain Insights

Following a decline in 2012, nominal and real-per-capita spending for medicines increased in the US, but growth in spending for medicines in the US remains at historical lows. The US pharmaceutical market recovered in 2013, posting positive...
DCAT Value Chain Insights

Looking at the first quarter of 2014, there have been several noteworthy deals and activity among contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). The key deal thus far in 2014 is the...
DCAT Value Chain Insights

Global and US venture-capital funding is up in the first quarter and the number of global and US IPOs increases year over year. Financing into the global and US biotech sector is an important barometer of the health of that sector and is an...